179 related articles for article (PubMed ID: 35500150)
1. Mucosa-associated lymphoid tissue lymphoma translocation protein 1 in rheumatoid arthritis: Longitudinal change after treatment and correlation with treatment efficacy of tumor necrosis factor inhibitors.
Wang F; Liu G; Xiang L; Yuan J; Tao Y; Zhang L; Zhang A; Chang X
J Clin Lab Anal; 2022 Jun; 36(6):e24449. PubMed ID: 35500150
[TBL] [Abstract][Full Text] [Related]
2. Serum CDC42 is increased during tumor necrosis factor inhibitor treatment, and its elevation correlates with satisfactory treatment response in rheumatoid arthritis patients.
Yang Y; Wu B; Tian P; Huang L
Int J Rheum Dis; 2023 Aug; 26(8):1521-1528. PubMed ID: 37382403
[TBL] [Abstract][Full Text] [Related]
3. MALT1 positively relates to Th17 cells, inflammation/activity degree, and its decrement along with treatment reflects TNF inhibitor response in ankylosing spondylitis patients.
Yuan J; Xiang L; Wang F; Zhang L; Liu G; Chang X; Zhang A; Tao Y
J Clin Lab Anal; 2022 Jul; 36(7):e24472. PubMed ID: 35622982
[TBL] [Abstract][Full Text] [Related]
4. Blood MALT1, Th1, and Th17 cells are dysregulated, inter-correlated, and correlated with disease activity in rheumatoid arthritis patients; meanwhile, MALT1 decline during therapy relates to treatment outcome.
Ye Z; Chen L; Fang Y; Zhao L
J Clin Lab Anal; 2022 Jan; 36(1):e24112. PubMed ID: 34788483
[TBL] [Abstract][Full Text] [Related]
5. MALT1 regulates Th2 and Th17 differentiation
Wang Q; Wang Y; Liu Q; Chu Y; Mi R; Jiang F; Zhao J; Hu K; Luo R; Feng Y; Lee H; Zhou D; Mi J; Deng R
Front Immunol; 2022; 13():913830. PubMed ID: 35967391
[TBL] [Abstract][Full Text] [Related]
6. JKAP correlates with lower disease risk and inflammation, and its increment during etanercept treatment associates with commendable treatment efficiency in rheumatoid arthritis patients.
Mou XY; Jin D; Zhang Q; Guan JT; Jin Y
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2654-2661. PubMed ID: 33829452
[TBL] [Abstract][Full Text] [Related]
7. Serum HDAC4 level in rheumatoid arthritis: Longitudinal change during treatment and correlation with clinical outcomes.
Mou X; Jin Y; Jin D; Guan J; Zhang Q
J Clin Lab Anal; 2022 Aug; 36(8):e24594. PubMed ID: 35792020
[TBL] [Abstract][Full Text] [Related]
8. MALT1 reflects inflammatory cytokines, disease activity, and its chronological change could estimate treatment response to infliximab in Crohn's disease patients.
Dong X; Chen X; Ren Y
J Clin Lab Anal; 2022 Oct; 36(10):e24650. PubMed ID: 36036788
[TBL] [Abstract][Full Text] [Related]
9. Potential role of MALT1 as a candidate biomarker of disease surveillance and treatment response prediction in inflammatory bowel disease patients.
Wu Z; Bi Y
J Clin Lab Anal; 2022 Feb; 36(2):e24130. PubMed ID: 34997981
[TBL] [Abstract][Full Text] [Related]
10. The implication of long non-coding RNA expression profile in rheumatoid arthritis: Correlation with treatment response to tumor necrosis factor inhibitor.
Wang Q; Huang X; Shao Y; Liu Q; Shen J; Xia J; Zhang Z; Wang C
Mod Rheumatol; 2023 Jan; 33(1):111-121. PubMed ID: 35141748
[TBL] [Abstract][Full Text] [Related]
11. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
[TBL] [Abstract][Full Text] [Related]
12. JNK pathway-associated phosphatase associates with rheumatoid arthritis risk, disease activity, and its longitudinal elevation relates to etanercept treatment response.
Sun L; Tu J; Chen X; Dai M; Xia X; Liu C; Zhou Y
J Clin Lab Anal; 2021 Apr; 35(4):e23709. PubMed ID: 33547838
[TBL] [Abstract][Full Text] [Related]
13. MALT1 in asthma children: A potential biomarker for monitoring exacerbation risk and Th1/Th2 imbalance-mediated inflammation.
Liu L; Gao Y; Si Y; Liu B; Liu X; Li G; Wang R
J Clin Lab Anal; 2022 May; 36(5):e24379. PubMed ID: 35353938
[TBL] [Abstract][Full Text] [Related]
14. Alternative expression pattern of MALT1-A20-NF-κB in patients with rheumatoid arthritis.
Wang X; Zhu L; Liao Z; Zhang F; Xu L; Xu Y; Chen S; Yang L; Zhou Y; Li Y
J Immunol Res; 2014; 2014():492872. PubMed ID: 24971370
[TBL] [Abstract][Full Text] [Related]
15. Management of gastric mucosa-associated lymphoid tissue lymphoma in patients with extra copies of the
Iwamuro M; Takenaka R; Nakagawa M; Moritou Y; Saito S; Hori S; Inaba T; Kawai Y; Toyokawa T; Tanaka T; Yoshino T; Okada H
World J Gastroenterol; 2017 Sep; 23(33):6155-6163. PubMed ID: 28970731
[TBL] [Abstract][Full Text] [Related]
16. Correlation of Ultrasound Synovitis Joint Count with Disease Activity and Its Longitudinal Variation with Treatment Response to Etanercept in Rheumatoid Arthritis.
Wang C; Qin Y; Xu J; Li G; Lei J; Zhang C; Deng H
Ultrasound Med Biol; 2021 Sep; 47(9):2543-2549. PubMed ID: 34175145
[TBL] [Abstract][Full Text] [Related]
17. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
[TBL] [Abstract][Full Text] [Related]
18. Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study.
Nakayama Y; Watanabe R; Murakami K; Murata K; Tanaka M; Ito H; Yamamoto W; Ebina K; Hata K; Hiramatsu Y; Katayama M; Son Y; Amuro H; Akashi K; Onishi A; Hara R; Yamamoto K; Ohmura K; Matsuda S; Morinobu A; Hashimoto M
Rheumatol Int; 2022 Jul; 42(7):1227-1234. PubMed ID: 35266034
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.
Favalli EG; Becciolini A; Carletto A; Conti F; Amato G; Fusaro E; Quartuccio L; Egan CG; Lo Monaco A; Benucci M; Salaffi F; Semeraro A; Parisi S; Ceccarelli F; Piazza I; Foti R
Rheumatol Int; 2020 Feb; 40(2):263-272. PubMed ID: 31435754
[TBL] [Abstract][Full Text] [Related]
20. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Mercer LK; Galloway JB; Lunt M; Davies R; Low AL; Dixon WG; Watson KD; ; Symmons DP; Hyrich KL
Ann Rheum Dis; 2017 Mar; 76(3):497-503. PubMed ID: 27502891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
